Allosteric modulator

Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update

Retrieved on: 
Thursday, March 24, 2022
Therapy, Patent, Investment, Clinical trial, Neurodegeneration, GAAP, Liver, Research, Program, Gaucher's disease, Glycogen storage disease, FIH, GD, Nasdaq, GLOBE, GBA1, Drug discovery, Neuron, Lists of diseases, Allosteric modulator, Development, Patient, GM1, Pharmaceutical industry, Medical imaging, Animal

BETHESDA, Md., March 24, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced its financial results for the full year ended December 31, 2021 and highlighted recent corporate accomplishments.

Key Points: 
  • Gain finished an extraordinary year of building value and accelerating its lead program to the clinic to provide a potentially disease modifying treatment for patients suffering from GBA1 Parkinsons Disease, commented Eric Richman, Chief Executive Officer of Gain.
  • As of December 31, 2021, the Companys cash position was $36.88 million, compared to $7.49 million as of December 31, 2020.
  • For the year-ended December 31, 2021, as compared to the year-ended December 31, 2020:
    Total operating expenses were $13,991 thousand compared to $3,508 thousand.
  • Cash and cash equivalents were $36.88 million as of December 31, 2021, compared to $7.49 million on December 31, 2020.

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Managed care, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Chemical compounds, Health sciences, Ketones, Pregnanes, Sterols, CDKL5 deficiency disorder, Ganaxolone, CDKL5, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Retrieved on: 
Monday, August 2, 2021
Enzyme kinetics, Branches of biology, Organic compounds, Chemistry, Proteins, Dipraglurant, Imidazopyridines, Organofluorides, Allosteric regulation, ASD, Dystonia, Allosteric modulator

Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Key Points: 
  • Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators

Retrieved on: 
Thursday, July 1, 2021
Allosteric modulator, Neuropharmacology, Allosteric regulation, Metabotropic glutamate receptor 2, Branches of biology, Chemistry, Cell biology

The study , published in Nature, was headed by Professor Georgios Skiniotis (Stanford University) in collaboration with the University of Copenhagen and Addex.

Key Points: 
  • The study , published in Nature, was headed by Professor Georgios Skiniotis (Stanford University) in collaboration with the University of Copenhagen and Addex.
  • Access to unique allosteric modulators stemming from Addexs expertise was invaluable as we elucidated these mGlu2 receptor structures, said Skiniotis.
  • The Nature publication explains how the mGlu2 receptor undergoes profound conformational transitions from an inactive to an active state.
  • Addex has developed unique capabilities that have allowed the industrialization of allosteric modulator discovery, including extensive expertise in targeting the mGlu2 receptor.

Addex Establishes At-The-Market ADS Equity Sale Program

Retrieved on: 
Wednesday, June 30, 2021
Indivior, Prospectus, Allosteric modulator, PAM

Copies of the prospectus supplement may be obtained for free from EDGAR on the SEC website at www.sec.gov.

Key Points: 
  • Copies of the prospectus supplement may be obtained for free from EDGAR on the SEC website at www.sec.gov.
  • Cantor Fitzgerald will use commercially reasonable efforts to sell all of the ADSs requested to be sold by Addex, consistent with its normal trading and sales practices.
  • Addex intends to use the net proceeds from the ATM program to advance development of its portfolio of proprietary allosteric modulator drug candidates.
  • Addexs GABAB PAM program has been licensed to Indivior PLC, which is focused on development for the treatment of addiction.

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

Retrieved on: 
Monday, June 14, 2021
Branches of biology, Neurochemistry, GABAA receptor positive allosteric modulators, Gába, GABAA receptor, Allosteric modulator, gamma-Aminobutyric acid, Allosteric regulation

PPD, a major depressive disorder that is under diagnosed in US, impacts approximately 1 in 7 women after giving birth.

Key Points: 
  • PPD, a major depressive disorder that is under diagnosed in US, impacts approximately 1 in 7 women after giving birth.
  • The active moiety in LPCN 1154 is an endogenous positive allosteric modulator of -aminobutyric acid ("GABAA") receptor.
  • Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107.
  • LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Friday, June 11, 2021
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Chemical compounds, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Ketones, Pregnanes, Sterols, Organic compounds, Ganaxolone, Allosteric modulator, Antidepressant

Vice President, Clinical Development

Key Points: 
  • Vice President, Clinical Development
    Speakers: Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer
    All of the above public webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com .
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Neurochemistry, Gába, Transmembrane receptors, GABAA receptor, GABA receptor, gamma-Aminobutyric acid, Allosteric regulation, Allosteric modulator

SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.

Key Points: 
  • SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.
  • While existing molecules target all GABA-A receptors indiscriminately, SAN711 selectively enhances the effects of GABA-A on 3 containing receptors.
  • Saniona also plans to continue to share its data on SAN711 and other preclinical programs in additional scientific and investor forums.
  • Saniona expects to begin a Phase 1 study of SAN711 in healthy volunteers in mid-2021, with data expected in early 2022.

Addex to Participate at the Benchmark Company Healthcare House Call Conference

Retrieved on: 
Monday, May 24, 2021
Enzyme kinetics, Branches of biology, Drug discovery, Biology, Allosteric regulation, Proteins, Allosteric modulator, Life sciences, ASD, Small molecule

Geneva, Switzerland, May 24, 2021 Addex Th e rapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,will participate at the virtual Benchmark Company Healthcare House Call Conference on May 26th, 2021 (09:00 16:30 EDT)

Key Points: 
  • Geneva, Switzerland, May 24, 2021 Addex Th e rapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,will participate at the virtual Benchmark Company Healthcare House Call Conference on May 26th, 2021 (09:00 16:30 EDT)
    Mr. Dyer will be available for virtual one-on-one meetings throughout the conference.
  • For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR .
  • Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
  • Addexs allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call

Retrieved on: 
Thursday, May 13, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Neurochemistry, Ketones, Sedatives, Anticonvulsants, Chloroarenes, Ganaxolone, Antidepressant, Allosteric modulator, Ketamine

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.